Could a simple gas help COPD patients avoid breathing tubes?
NCT ID NCT07191470
First seen Jun 26, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This study tested whether a mild gas medicine called isoflurane, given through a special device (AnaConDa), helps people with severe COPD flare-ups feel more comfortable during non-invasive ventilation (a breathing mask). Ten adults with COPD and high carbon dioxide levels took part. The goal was to see if the gas could reduce agitation and the need for a breathing tube. Researchers monitored vital signs and comfort levels over 24 hours.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- isoflurane gas
- What this could lead to
- If it works, this could offer a way to make breathing support more comfortable for COPD patients during severe flare-ups, potentially reducing the need for a breathing tube.
- What could go wrong
- This is a very small, early study with only 10 participants, so results may not apply to everyone. Risks include too much sedation, low blood pressure, or slowed breathing.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
10 people
The number who actually took part.
- Started
-
Apr 2023
- Finished
-
Jan 2024
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria 1\. A confirmed diagnosis of COPD who had been admitted to the ICU due to acute exacerbation and hypercapnic respiratory failure requiring non-invasive ventilation. Exclusion Criteria: 1. Any known allergy or contraindication to isoflurane, including hypersensitivity to isoflurane or other volatile anaesthetics. 2. A history of malignant hyperthermia or hepatic dysfunction suspected to be linked to prior exposure to volatile anaesthetics. 3. contraindications for NIV were taken into account, such as severe respiratory failure necessitating immediate invasive mechanical ventilation, facial trauma, burns, or anatomical abnormalities preventing proper mask fit, uncontrolled vomiting or excessive airway secretions, pneumothorax, and neurological impairment with a Glasgow Coma Scale (GCS) score of less than 12 and difficulty in airway protection. 4. Patients with hemodynamic instability, including shock unresponsive to fluid resuscitation, severe arrhythmias, or refractory hypotension unmanageable with NIV alone. 5. Pregnant patients or individuals who had recently undergone upper airway surgery or tracheostomy.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Chronic obstructive airway disease are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Pandit Bhagwat Dayal Sharma Postgraduate Institute of Medical Sciences
Rohtak, Haryana, 124001, India
More trials for these conditions
Other studies related to the condition(s) this trial covers.